Highest-materiality recent filing
NewAmsterdam Pharma shareholders approve 2026 ESPP, re-elect directors at AGM
Shareholders approved 2026 Employee Stock Purchase Plan; up to 1,150,000 ordinary shares available, 15% discount on lower of start/end market price.
NewAmsterdam Pharma reports Q1 net loss of $48.4M; PREVAIL interim analysis planned for 4Q26
Net loss $48.4M for Q1 2026, compared to net loss $39.5M in Q1 2025.
NewAmsterdam Pharma CAO Louise Kooij to depart Aug 31, 2026; severance terms set
Louise Kooij to step down as Chief Accounting Officer effective August 31, 2026.
NewAmsterdam Pharma files updated corporate presentation, no specific details disclosed
Company posted an updated investor presentation on its website on March 2, 2026.
NewAmsterdam Pharma reports $728.9M cash, obicetrapib regulatory decisions expected 2H26
Regulatory decisions from EMA, UK, Switzerland for obicetrapib monotherapy & FDC expected in 2H26.
NewAmsterdam provides pipeline update; cash ~$729M; EMA decision expected 2H26
Unaudited cash, cash equivalents and marketable securities ~$729M as of Dec 31, 2025.
NewAmsterdam Pharma Q3 net loss widens to $72M; EMA accepts MAAs for obicetrapib
Cash, equivalents and securities $756M as of Sep 30, 2025, down from $834.2M at Dec 31, 2024.
NewAmsterdam Pharma posts updated corporate investor presentation on Sep 2, 2025
Presentation posted on company website and furnished as an exhibit to the Form 8-K.
EMA validates MAA for NewAmsterdam's obicetrapib monotherapy and FDC with ezetimibe
EMA will review Phase 3 BROADWAY, BROOKLYN and TANDEM trials supporting obicetrapib 10 mg and obicetrapib/ezetimibe FDC.
NewAmsterdam enters supply agreement with Menarini for obicetrapib products
Supply Agreement dated Aug 12, 2025 with Menarini for obicetrapib monotherapy and obicetrapib/ezetimibe fixed-dose combo.
NewAmsterdam Q2 net loss narrows to $17.4M; obicetrapib data published in NEJM and Lancet
Cash, equivalents and securities $783.3M at June 30, 2025, down from $834.2M at Dec 31, 2024.
NewAmsterdam: Obicetrapib significantly reduces p-tau217 in ApoE4 carriers in BROADWAY
p-tau217 reduced in full analysis set (p=0.0019, n=1,515) and ApoE4 carriers (p=0.0215, n=367).
NewAmsterdam Pharma amends CSO Kastelein's employment agreement with enhanced severance
Amended agreement effective July 1, 2025; replaces November 2022 pact.
NewAmsterdam Pharma holds R&D Day; no material updates extracted from filing
Company hosted R&D Day on June 11, 2025 in New York City with live webcast.
Statistically significant lower absolute change in p-tau217 over 12 months vs placebo in full ITT (p<0.002) and ApoE4 carriers (p=0.0215).
All nine proposals approved at NewAmsterdam Pharma 2025 AGM
Quorum of 83.6M ordinary shares (74.45%) voted; all nine agenda items passed.
NewAmsterdam Pharma reports Q1 net loss $39.5M; cash $808.5M; EMA submission on track for 2H25
Cash $808.5M at Mar 31, 2025, down from $834.2M at Dec 31, 2024.
NewAmsterdam Pharma Reports Phase 3 BROADWAY and TANDEM Data Published in NEJM and Lancet
BROADWAY trial showed 33% LDL-C reduction (p<0.0001) vs placebo and a 21% relative reduction in MACE (HR=0.79).
NewAmsterdam Pharma appoints Adele Gulfo as independent director
Adele Gulfo, former CEO of Sumitomo Pharma America's Biopharma Unit, joins Board effective April 15, 2025.
NewAmsterdam reports FY2024 net loss $241.6M, cash $834M; EMA submission on track for 2H25
Cash, cash equivalents and marketable securities totaled $834.2M at Dec 31, 2024, up from $340.5M.
NewAmsterdam provides 2024-2025 update: Phase 3 data, $835M cash, EMA filing in 2H25
BROADWAY Phase 3 met primary endpoint: 33% LS mean LDL-C reduction (p<0.0001); exploratory MACE reduction of 21%.
NewAmsterdam Pharma prices $416.5M upsized public offering; net proceeds ~$452.6M
Pricing of 12,117,347 ordinary shares at $24.50/share and 4,882,653 pre-funded warrants at $24.4999/warrant.
NewAmsterdam reports positive Phase 3 BROADWAY topline: 33% LDL-C reduction, 21% MACE reduction
Primary endpoint met: LS mean LDL-C reduction of 33% (p<0.0001) vs placebo at day 84 on top of maximally tolerated therapies.
NewAmsterdam Pharma terminates $150M ATM equity offering program
Company delivered notice to Cowen and TD Cowen to suspend and terminate ATM prospectus supplement dated August 9, 2024.
NewAmsterdam Pharma reports positive Phase 3 TANDEM topline data; FDC lowers LDL-C 48.6% vs placebo
Fixed-dose combination of obicetrapib 10 mg and ezetimibe 10 mg achieved LS mean LDL-C reduction of 48.6% (p<0.0001) vs placebo at day 84.
LDL-C mean reduction vs placebo 36.3% at day 84 (p<0.0001), sustained at 41.5% at day 365.
NewAmsterdam Pharma Q3 net loss $16.6M; Phase 3 TANDEM topline expected Q4 2024
Cash $422.7M as of Sep 30, 2024, up from $340.5M at Dec 31, 2023.
NewAmsterdam Pharma to restate 2022 and 2021 financials due to EPS calculation errors
Audit committee concluded 2021 and 2022 financial statements should not be relied upon due to net loss per share errors.
NewAmsterdam Pharma enters $150M ATM equity offering with TD Cowen as agent
Amended Sales Agreement replaces Cowen and Company with TD Cowen as sole sales agent.
NewAmsterdam reports positive Phase 3 BROOKLYN data; Q2 net loss $39M
Phase 3 BROOKLYN met primary endpoint: LS mean LDL-C reduction 36.3% at day 84 (p<0.0001), sustained at day 365 (-41.5%); safety comparable to placebo.
NAMS: Phase 3 BROOKLYN trial of obicetrapib meets primary endpoint; LDL-C down 36.3% at day 84
LDL-C reduced 36.3% vs placebo at day 84 and 41.5% at day 365, both p<0.0001.
NewAmsterdam appoints McKenna and Joustra to board; Slootweg resigns
Sander Slootweg resigned from the Board effective July 16, 2024; no disagreement cited.
NewAmsterdam Pharma obtains composition of matter patent for obicetrapib extending IP to July 2043
USPTO issued patent 12,006,305 covering amorphous obicetrapib hemicalcium, the product form for potential commercialization.
NewAmsterdam Pharma shareholders approve all proposals at 2024 AGM
Quorum of 57.6M shares (64% of eligible) voted; all seven proposals passed.
NewAmsterdam Pharma Q1 net loss $93.8M; Phase 3 readouts on track for 2024
Enrolled over 9,500 patients in Phase 3 PREVAIL CVOT; topline data from BROOKLYN in Q3 2024 and BROADWAY in Q4 2024.
NewAmsterdam Pharma appoints Juliette Audet as CBO, effective April 1, 2024
Juliette Audet appointed Chief Business Officer, effective April 1, 2024.
NewAmsterdam Pharma posts updated investor presentation; no material new data
Company posted updated corporate investor presentation on its website on March 4, 2024.
NewAmsterdam Pharma FY2023 net loss $176.9M; cash $340.5M; expects Phase 3 readouts in 2024
FY2023 net loss of $176.9M ($2.15 per share) vs $11.5M loss prior year; revenue fell to $14.1M from $102.7M.
On April 15, 2025, the board of directors (the “Board”) of NewAmsterdam Pharma Company N.V. (the “Company”) appointed Adele Gulfo to serve as a member of the Board.
On July 16, 2024, Sander Slootweg notified NewAmsterdam Pharma Company N.V. (the “Company”) of his decision to resign as a member of the Company’s board of directors (the “Board”) effective immediately.
On July 16, 2024, the Board appointed Wouter Joustra and Mark C. McKenna to serve as members of the Board.
On July 16, 2024, the Board appointed Wouter Joustra and Mark C. McKenna to serve as members of the Board.
In connection with Ms. Audet’s appointment as CBO, the Company’s board of directors (the “Board”) and Ms. Audet determined, as of March 28, 2024, that she will resign, effective April 1, 2024, from the Board.
On April 1, 2024, NewAmsterdam Pharma Company N.V. (the “Company”) announced the appointment of Juliette Audet as Chief Business Officer (“CBO”) of the Company.
Max materiality 0.90 · Median 0.65 · Most common event other_material